Uscom

ASX MEDIA RELEASE

Two New USCOM Monitors Get Australian TGA Clearance

- Two new USCOM Haemodynamic Monitors Approved
- Strategic Internationalisation Expands into Australian Market
- Growing Portfolio of Specialised Clinical Devices

SYDNEY, Australia, Thursday 27th May 2021: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today notified the market that Uscom has received Therapeutic Goods Administration (TGA) issued Free Sales Certificates for two new haemodynamic monitoring devices. TGA clearance was for the USCOM O2 and USCOM Basic monitors, specialised forms of the USCOM 1A non-invasive ultrasound Doppler hemodynamic monitor.

Background:

The USCOM 1A is sold worldwide and is installed into many of the world's leading hospitals for the diagnosis and treatment of sepsis, fluid management, heart failure, hypertension and preeclampsia in adults, children and neonates. Over 1500 USCOM units have been sold globally over the last 10 years generating ~$25m revenue, with over 400 peer reviewed publications, and it is this success and diverse utility which has encouraged the development of specialised technologies for different clinical uses. The USCOM O2 is the most advanced version of the USCOM series so far, measuring 36 parameters including systemic oxygen delivery, which is a critical measure of circulatory effectiveness. The USCOM Basic displays 12 fundamental hemodynamic parameters, and was developed as a competitive product for price sensitive tenders. The USCOM 1A will continue as the lead device of the series, while the USCOM O2 and USCOM Basic are expected to deliver new sales revenue as high and low priced options to meet differing hospital budgets and clinical needs.

Commentary:

Executive Chairman of Uscom, Professor Rob Phillips said *"This approval is a result of our internationalisation and product diversification strategy initiated 2 years ago. As revenue continues to grow, Uscom is strategically expanding its product range to meet international markets and the USCOM series remains our cornerstone technologies. We have four distinct and specialised product suites which will eventually become discrete divisions of Uscom Limited, specialising in cardiac ultrasound, hypertension and vascular health, pulmonary monitoring and tele and eHealth. Concurrently we are diversifying into new markets as we focus on creating SE Asia, Europe, Middle East and US creating discrete profitable entities, modelled on our China success. We have built the foundations of a strong global medical device company, and mitigating product, currency and geopolitical risk is important to shield us from uncertainty in uncertain times. This TGA clearance further advances this strategy."*

Uscom devices:

Uscom manufactures and markets the **USCOM 1A** haemodynamic monitor, the Uscom **BP+**, central blood pressure and vascular health monitor, the Uscom **SpiroSonic** digital ultrasonic spirometers, and the **VENTITEST** and **VENTITEST-S** ultrasonic ventilator calibrators for optimising respiratory device performance.

For personal use only

For personal use only

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary